Law.com Subscribers SAVE 30%
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
IP News
Federal Circuit: Affirms Preliminary Injunction on Cancer Assays
On July 12, 2024, a Federal Circuit panel of Chief Judge Moore and Judges Taranto and Chen issued a unanimous opinion, authored by Chief Judge Moore, in Natera, Inc. v. NeoGenomics Labs, Inc., Case Nos. 2024-1324; 2024-1409. The panel affirmed the United States District Court for the Middle District of North Carolina's grant of a preliminary injunction barring NeoGenomics from making, using, selling, advertising or distributing its RaDaR assay. Slip Op. at 2.
Natera, Inc. is a "research-focused healthcare compan[y] operating in the oncology testing industry" that "manufacture[s] products used for early detection of cancer relapse." Id. Natera asserted two patents (U.S. Patent No. 11,519,035 (the '035 Patent) and U.S. Patent No. 11,530,454 (the '454 Patent)) related to methods of amplifying and detecting cell-free DNA and circulating tumor DNA against NeoGenomics Laboratories, Inc. (NeoGenomics) Id. at 2-3. While "Natera uses the methods claimed in the '035 and '454 patents in its Signatera product," "NeoGenomics offers a competing product under the brand name RaDaR." Id. at 3. Both Signatera and RaDaR are used to "identify ctDNA within the bloodstream to assess the efficacy of cancer treatment and the risk of cancer recurrence." Id.
This premium content is locked for Entertainment Law & Finance subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
How AI Has Affected PR
When we consider how the use of AI affects legal PR and communications, we have to look at it as an industrywide global phenomenon. A recent online conference provided an overview of the latest AI trends in public relations, and specifically, the impact of AI on communications. Here are some of the key points and takeaways from several of the speakers, who provided current best practices, tips, concerns and case studies.
The DOJ's New Parameters for Evaluating Corporate Compliance Programs
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.